Loading
NASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$6.54
−$0.06 · -0.91%
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Previous close
$6.54
−$0.06 · -0.91%
After-hours
$6.54
$0.00 · 0.00%
Sep 4, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Day range
Current $6.54
52-week range
Current $6.54
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
40
Expensive
Sentiment
58
Mixed
Risk
96
Extreme Risk
Momentum
32
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Day range
Current $6.54
52-week range
Current $6.54
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 8.65M USD | 8.19M USD | 6.71M USD | 23.54M USD | 4.43M USD |
| Cost of goods sold | 1.1M USD | 2.3M USD | 3.35M USD | 10.98M USD | 1.89M USD |
| Gross profit | 7.54M USD | 5.89M USD | 3.36M USD | 12.56M USD | 2.54M USD |
| Research and development | 201.31K USD | 454.23K USD | 134.7K USD | 200K USD | — |
| Selling, general, and administrative | 1.57M USD | 3.44M USD | 1.27M USD | 2.17M USD | 86.1K USD |
| Operating expenses | 1.78M USD | 3.89M USD | 1.4M USD | 2.37M USD | 86.1K USD |
| Interest income | 142.02K USD | 337.51K USD | 165.34K USD | 42.25K USD | — |
| Interest expense | — | — | — | 8K USD | — |
| Depreciation and amortization | — | — | 13.04K USD | 6.25K USD | — |
| Operating income | 5.77M USD | 2M USD | 1.96M USD | 10.2M USD | 2.46M USD |
| Net income | 6.4M USD | 2.37M USD | 2.25M USD | 10.01M USD | 2.54M USD |
Company facts updated Sep 5, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
